THC-CBD Treatment Dramatically Reduces Agitation in Dementia Trial

A U.S. clinical trial found a medically formulated THC-CBD treatment significantly reduced agitation in people with late-stage dementia.

Benefits appeared within 2 weeks and were sustained through 12 weeks compared with placebo.

The results offer a potential new option for a hard-to-treat symptom in hospice-eligible Alzheimer’s and other dementia patients.

Researchers caution that this is a specific prescription-style formulation, not the same as commercial cannabis products.